Eosinophilic granulomatosis with polyangiitis
EGPA / Churg-Strauss · Respiratory
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
EGPA is an ANCA-associated small-vessel vasculitis featuring asthma, marked eosinophilia and multisystem involvement (lung, nerve, heart, skin, GI). It often emerges in difficult asthma; cardiac and neurological involvement drive mortality and dictate treatment intensity.
Red flags
- Cardiac involvement (heart failure, arrhythmia, troponin rise)
- Mononeuritis multiplex / foot or wrist drop
- Gastrointestinal ischaemia or bleeding
- Alveolar haemorrhage or rapidly progressive renal impairment
Assessment
Differential diagnosis
- Severe eosinophilic asthma
- Hypereosinophilic syndrome
- ABPA
- Other ANCA-associated vasculitides
- Parasitic/drug-induced eosinophilia
- Eosinophilic pneumonia
Investigations
- Full blood count (marked eosinophilia)
- ANCA (often MPO/p-ANCA positive in a subset)
- HRCT chest (transient/peripheral infiltrates)
- Nerve conduction studies for mononeuritis multiplex
- Cardiac assessment (ECG, troponin, echo, cardiac MRI)
- Tissue biopsy (eosinophilic vasculitis/granulomas) where feasible; urinalysis and renal function
Management
- Suspect in asthma with eosinophilia and new multisystem features (neuropathy, cardiac, skin, GI)
- Quantify eosinophilia and test ANCA
- Map organ involvement, prioritising cardiac and neurological assessment
- Obtain tissue confirmation where safe and feasible
- Risk-stratify by major-organ (heart, nerve, kidney, GI) involvement
- Induce remission with high-dose corticosteroids for all
- Add cyclophosphamide or rituximab for severe/organ-threatening disease
- Treat cardiac involvement urgently with cardiology input
- Transition to maintenance immunosuppression and taper steroids
- Use mepolizumab as a steroid-sparing agent in relapsing/refractory non-severe disease and follow long term
Drugs & doses
Prednisolone 1 mg/kg/day PO (up to 60 mg), with IV methylprednisolone pulses for organ-threatening disease
Cyclophosphamide (IV pulsed or oral) for severe/organ-threatening disease
Rituximab 375 mg/m2 weekly x4 or 1 g x2 as alternative induction
Mepolizumab 300 mg SC every 4 weeks (steroid-sparing, relapsing disease)
Azathioprine / methotrexate for maintenance
Disposition
Urgent rheumatology/respiratory vasculitis service; cardiology for cardiac disease; immunosuppression with specialist monitoring.
Complications & pitfalls
- Cardiomyopathy and arrhythmia (leading cause of death)
- Permanent peripheral neuropathy
- Gastrointestinal perforation/ischaemia
- Treatment-related infection and steroid toxicity
Exam pearls
- Cardiac involvement is the main driver of mortality — assess the heart early
- Only ~40% are ANCA-positive; a negative ANCA does not exclude EGPA
- Mepolizumab is licensed as a steroid-sparing agent in relapsing/refractory EGPA
- Beware EGPA unmasked during leukotriene-antagonist or biologic steroid tapering in asthma
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.